



## News Release

### **InforSense® and GeneGo Join Forces to Deliver Integrated Pathway-Based Workflows to Enable Systems Biology Research**

- **Integration of InforSense and GeneGo Products to Provide Flexible, High-Throughput Pathway-centric Data Analysis**
- **GeneGo joins InforSense's Open Workflow Partner Network as 20<sup>th</sup> Member**

**London, UK and Cambridge, MA, USA, April 11, 2006** - InforSense Ltd., the leader in integrative analytics platforms, today announced that the company has joined forces with GeneGo, a leading provider of systems biology tools and databases. The companies are integrating their technologies to allow researchers to better probe their data and share their work process across different research domains. GeneGo has also joined the InforSense Open Workflow Partner Network.

The integration of GeneGo's unique reference system for curated pathway analysis and InforSense's integrated, interactive workflow-based data mining technology allows researchers to query their data and share their results across the research and development value chain. In addition to the integration of InforSense KDE and MetaCore, which is already available, the companies are in the process of integrating InforSense KDE with both MetaDrug and MetaBase. Customer feedback supports integration of GeneGo's software suite with the proven InforSense workflow technology, as researchers will be enabled to bridge domains such as genomics and metabolomics with high confidence data using a systems biology approach. In addition, users will be able to annotate pathway data with experimental results and clinical data and thereby better predict patient outcomes.

"The collaboration between InforSense and GeneGo will deliver to thousands of users the needed environment for leveraging high-throughput biology and chemistry data more effectively for better and faster decision-making within the life science industry," said Julie Bryant, Vice President of Business Development of GeneGo. "InforSense workflows enable life science researchers to compose and execute scientific analyses quickly and easily without programming, sharing both methods and results with co-workers."

"MetaCore has grown to become a key component in the research toolbox in the life sciences, particularly within the pharmaceutical industry, and we are pleased to have the opportunity to work with GeneGo," commented Dr. Jonathan Sheldon, Chief Scientific Officer, InforSense. "The integration of pathway analysis with InforSense KDE is a key component of our multidisciplinary analytics platform for Systems Biology."

## **About GeneGo**

GeneGo develops tools for integration and systems level analysis of high-throughput experimental data in human biology and medicinal chemistry. The flagship product, MetaCore™, is designed to assist scientists in drug target selection, validation, and identification of molecular biomarkers for disease states. MetaCore™ is an integrated analytical suite with intuitive interface, data parsers and visualization tools and flexible network building algorithms working on the proprietary content of MetaBase™ - our manually curated database on human biology in norm and diseases. The most comprehensive database in the field, MetaBase™ allows one to network over 90% of the known human proteins via physical protein-protein, protein-DNA and protein-compound interactions. GeneGo's second product, MetaDrug™, deals with prediction of human metabolism and toxicity of novel small molecules and compounds. Customers include many of the largest pharmaceutical companies and leading university labs.

GeneGo was founded in 2000 by Dr. Tatiana Nikolskaya, then a wet lab molecular biologist at the University of Chicago, The company headquarters are located in St. Joseph, MI. GeneGo has business offices in San Diego, CA, Munich, Germany and a research facility in Moscow, Russia.

## **About InforSense**

InforSense Ltd., the leader in integrative analytics, enables organizations to orchestrate and optimize their business-critical decision-making processes. Leading pharmaceutical and biotechnology, consumer goods, financial services companies, and research institutes are using the company's flagship product, InforSense KDE, to enhance productivity across life science R&D, healthcare, and business analytics. The company is privately held, with European headquarters in London, UK and North American headquarters in Cambridge, Massachusetts.

## **About InforSense KDE**

Using InforSense KDE, enterprises rapidly integrate and deliver virtually any data source, analytic software tool, service or application within a single informatics framework. Users link these components via visual workflows to dynamically answer any question using their data, however complex or transient. Organizations can also mine their analytical processes to discover and deploy expertise and best practices. InforSense KDE provides an open, extensible service-oriented architecture, built using industry standards including J2EE, XML, and WSDL. InforSense IOE is a state-of-the-art solution for enterprise-wide integrative analytics using Oracle's advanced information management and processing capabilities.

## **About InforSense Partner Network**

The InforSense Partner Network provides interoperability between industry leading technologies via InforSense KDE. Mutual customers benefit from proven integration between their tools of choice across scientific and business analytics via an intuitive visual workflow interface.

For more information visit [www.inforsense.com](http://www.inforsense.com)

InforSense, TextSense and the InforSense logo are registered trademarks of InforSense Limited. All rights reserved. All other trademarks mentioned in this document are the property of their respective owners.

**For more information please contact:**

Tracy Coffey Donahue  
Corporate Communications Officer  
InforSense Ltd.  
+1 857 919 9975  
[tcdonahue@inforsense.com](mailto:tcdonahue@inforsense.com)